Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
Rhea-AI Summary
Tevogen (Nasdaq: TVGN) said Tevogen.AI’s PredicTcell™ training is nearing completion and the company has begun commercial-readiness steps.
The model was trained on one of the industry’s largest curated peptide datasets, now uses >180 features and shows an approx. 10% improvement in precision. An internal application portal has been launched to serve the model and enable future customer-facing use.
AI-generated analysis. Not financial advice.
Positive
- PredicTcell near completion of training
- Model trained on one of the industry’s largest curated peptide datasets
- Feature expansion now exceeds 180 parameters
- Approximate 10% improvement in precision
- Initial internal application portal deployed
- Exploring co-development partnerships for broader application
Negative
- PredicTcell is not yet commercially deployed
- Platform still requires significant wet lab validation
- Commercial pathways are only being explored, not finalized
News Market Reaction – TVGN
On the day this news was published, TVGN declined 7.28%, reflecting a notable negative market reaction. Argus tracked a trough of -8.9% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $29.57M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Scanner shows biotechnology peers SLS and ELTX moving up, but sector flag is false and target direction is unspecified, pointing to company-specific drivers for TVGN.
Previous AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Conference appearance | Positive | +3.1% | CIO speaking at Microsoft Fabric conference on Tevogen.AI applications. |
| Mar 13 | AI platform update | Positive | -15.7% | PredicTcell™ beta showed improved recall, precision and expanded AI infrastructure. |
| Sep 25 | AI data scale-up | Positive | +1.5% | PredicTcell™ beta expanded to multi‑billion record datasets with higher recall. |
| Sep 10 | Conference panel | Positive | -1.4% | CIO joined Databricks DATA + AI World Tour panel on scaling with PredicTcell™. |
| Aug 11 | Stockholder letter | Positive | +8.8% | Letter highlighted strong capital position and launch of AI‑driven PredicTcell™. |
AI-tag news for TVGN has produced mixed reactions: 3 aligned, 2 divergent, with an average next-day move of -0.74%.
Over the past year, Tevogen’s AI-related updates have focused on the PredicTcell™ platform and leadership visibility. Events include large data expansions, beta performance metrics, and conference appearances, plus a stockholder letter emphasizing AI expansion and partnerships with Microsoft and Databricks. Price reactions have ranged from -15.67% to +8.83%, showing that AI headlines alone have not produced consistent upside. Today’s PredicTcell™ training and portal update fits into this ongoing buildout of the Tevogen.AI ecosystem.
Historical Comparison
In the past 5 AI-tag announcements, TVGN’s average next-day move was -0.74%, with both sizable gains and losses, indicating volatile but inconsistent reactions.
AI-tag history shows PredicTcell™ evolving from launch and data expansion into beta performance gains and growing external visibility through conferences and stockholder communications.
Market Pulse Summary
The stock moved -7.3% in the session following this news. A negative reaction despite technical progress would fit prior AI headlines that sometimes preceded declines, including a -15.67% move on an earlier PredicTcell™ update. The company reported an approximate 10% precision improvement and more than 180 features, but past data show AI announcements alone have not guaranteed support, with average AI-tag moves around -0.74%. Execution on commercialization and broader strategy has historically influenced how durable sentiment becomes.
Key Terms
machine learning technical
immunologically active peptides medical
wet lab validation medical
AI-generated analysis. Not financial advice.
WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress within its artificial intelligence initiative, Tevogen.AI, including the near completion of its PredicTcell™ training algorithm and early steps toward commercial readiness.
PredicTcell™, Tevogen.AI’s proprietary machine learning model designed to identify immunologically active peptides, is approaching the final stages of its training phase. The model has been trained on one of the industry’s largest curated peptide datasets, with feature expansion now exceeding 180 parameters, contributing to an approximate
As development progresses, the Company has begun evaluating potential co-development partnerships to support broader application of the platform. These efforts are grounded in addressing a fundamental challenge in drug development, high-confidence target identification, which today often requires significant wet lab validation. By leveraging advanced predictive modeling, Tevogen.AI aims to reduce development timelines, material costs, and overall experimental burden.
To support this transition, Tevogen.AI has developed an initial version of an internal application and portal designed to serve the PredicTcell™ model in a scalable and user-friendly environment. This system is intended to streamline internal workflows while also serving as the foundation for a potential future customer-facing platform.
“Advancing PredicTcell toward completion marks an important milestone in our AI strategy,” said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI. “As we begin exploring commercial pathways, our focus remains on maintaining scientific rigor while building scalable tools that can extend the impact of our platform beyond internal use.”
About Tevogen
Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.
Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.
Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.
Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: the potential transactions and the potential benefits of the transactions; Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: risks inherent in diligence and negotiation of the proposed transactions; the risk that the transactions may not be consummated on favorable terms or at all; the risk that the expected benefits of the transactions may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contact
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dc577aeb-e6dd-4eaa-ba5e-c5b1cac3e0b0
